Advertisement

Antihistamines

  • Jerry W. Snow
  • R. Brent Furbee
Reference work entry

Abstract

By the turn of the twentieth century, interest in allergic response and particularly the phenomenon of anaphylaxis had become intense. In 1902, Portier and Richet provided further focus for the study by developing the concept of altered animal reactivity, which they termed allergy [1]. Of the biologic amines released in the inflammatory process, histamine was the first described, originally termed β-aminoethylimidazole. Histamine’s actions on the gut, bronchioles, and heart were reported in 1910 [2, 3]. The work on the receptor theory of drug action was well under way when the first articles on anaphylaxis were published.

References

  1. 1.
    Portier P, Richet C. De l’ action anaphylactique de certains venins. C R Soc Biol. 1902;54:170–2.Google Scholar
  2. 2.
    Barger G, Dale H. The presence in ergot and physiological activity of β-iminazoylethylamine. J Physiol. 1910;30:38–40.Google Scholar
  3. 3.
    Dale H, Laidlaw P. The Physiological action of b-iminazoylethylamine. J Physiol. 1910;41:341–4.Google Scholar
  4. 4.
    Clark AJ. The mode of action of drugs on cells. London: Arnold; 1933.Google Scholar
  5. 5.
    Ash A, Schild H. Receptors mediating some actions of histamine. Br J Pharmacol. 1966;27:427–9.Google Scholar
  6. 6.
    Black J. Definition and antagonism of H2 receptors. Nature. 1972;236:385–90.PubMedCrossRefGoogle Scholar
  7. 7.
    Emanuel M. Histamine and the antiallergic antihistamines: a history of their discoveries. Clin Exp Allergy. 1999;29 Suppl 3:1–11.PubMedGoogle Scholar
  8. 8.
    Slater JW, Zechnich AD, Haxby DG. Second-generation antihistamines: a comparative review. Drugs. 1999;57:31–47. PubMed.PubMedCrossRefGoogle Scholar
  9. 9.
    Simons FE, Simons KJ. The pharmacology and use of H1-receptor-antagonist drugs. N Engl J Med. 1994;330:1663–70.PubMedCrossRefGoogle Scholar
  10. 10.
    Hill SJ. Multiple histamine receptors: properties and functional characteristics. Biochem Soc Trans. 1992;20:122–5.PubMedCrossRefGoogle Scholar
  11. 11.
    Leurs R, Smit MJ, Timmerman H. Molecular pharmacological aspects of histamine receptors. Pharmacol Ther. 1995;66:413–63.PubMedCrossRefGoogle Scholar
  12. 12.
    Scherkl R, Hashem A, Frey HH. Histamine in brain-its role in regulation of seizure susceptibility. Epilepsy. 1991;10:111–8.CrossRefGoogle Scholar
  13. 13.
    Wada H, Inagaki N, Itowi N, Yamatodani A. Histaminergic neuron system: morphological features and possible functions. Agents Actions. 1991;33:11–27.PubMedGoogle Scholar
  14. 14.
    Reiner PB, Kamondi A. Mechanisms of antihistamine-induced sedation in the human brain: H1 receptor activation reduces a background leakage of a potassium current. Neuroscience. 1994;59:579–88.PubMedCrossRefGoogle Scholar
  15. 15.
    Emamhadi M, Mostafazadeh B, Hassanijirdehi M. Tricyclic antidepressant poisoning treated by magnesium sulfate: a randomized, clinical trial. Drug Chem Toxicol. 2012;35:300–3. PubMed.PubMedCrossRefGoogle Scholar
  16. 16.
    Simons FER. Non-cardiac adverse effects of antihistamines (H1-receptor antagonists). Clin Exp Allergy. 1999;29:125–32.PubMedCrossRefGoogle Scholar
  17. 17.
    Sangalli BC. Role of the central histaminergic neuronal system in the CNS toxicity of first generation H1-antagonists. Prog Neurobiol. 1997;52:145–57.PubMedCrossRefGoogle Scholar
  18. 18.
    Kamei C, Ishizawa K, Kakinoki H, Fukunaga M. Histaminergic mechanisms in amygdaloid-kindled seizures in rats. Epilepsy Res. 1998;30:187–94.PubMedCrossRefGoogle Scholar
  19. 19.
    Scherkl R, Hashem A, Frey HH. Importance of histamine for seizure susceptibility. Agents Actions. 1991;33:85–9.PubMedGoogle Scholar
  20. 20.
    Seger DL, Hantsch C, Zavoral T, Wrenn K. Variability of recommendations for serum alkalinization in tricyclic antidepressant overdose: a survey of U.S. Poison Center medical directors. J Toxicol Clin Toxicol. 2003;41:331–8. PubMed.Google Scholar
  21. 21.
    Yokoyama H, Sato M, Iinuma K, Onodera K, Watanabe T. Centrally acting H1 antagonist promote the development of amygdala kindling in rats. Neurosci Lett. 1996;217:194–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Amabeoku GJ, Chikuni O. Cimetidine-induced seizures in mice. Biochem Pharmacol. 1993;46:2171–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Kakinoki H, Ishizawa K, Fukunaga M, Fujii Y, Kamei C. The effects of histamine H3-receptor antagonists on amygdaloid kindled seizures in rats. Brain Res Bull. 1998;46:461–5.PubMedCrossRefGoogle Scholar
  24. 24.
    Smit MJ, Hoffmann M, Timmerman H, Leurs R. Molecular properties and signalling pathways of the histamine H1 receptor. Clin Exp Allergy. 1999;29:19–28.PubMedGoogle Scholar
  25. 25.
    Kukovetz WR. Effect of ortho-(beta-diethylaminoethoxy)phenylpropiophenone × HCl (etafenone) on the dynamics, metabolism, O2-utilization and coronary flow of heart. Arzneimittelforschung. 1969;19:1672–7.PubMedGoogle Scholar
  26. 26.
    Rinder CS, D’Amato SL, Rinder HM, Cox PM. Survival in complicated diphenhydramine overdose. Crit Care Med. 1988;16:1161–2.PubMedCrossRefGoogle Scholar
  27. 27.
    Wang WX, Ebert SN, Liu XK, Chen YW, Drici MD, Woosley RL. “Conventional” antihistamines slow cardiac repolarization in isolated perfused (Langendorff) feline hearts. J Cardiovasc Pharmacol. 1998;32:123–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Zareba W, Moss AJ, Rosero SZ, Hajj-Ali R, Konecki J, Andrews M. Electrocardiographic findings in patients with diphenhydramine overdose. Am J Cardiol. 1997;80:1168–73.PubMedCrossRefGoogle Scholar
  29. 29.
    Barbey JT, Anderson M, Ciprandi G, Frew AJ, Morad M, Priori SG, et al. Cardiovascular safety of second-generation antihistamines. Am J Rhinol. 1999;13:235–43.PubMedCrossRefGoogle Scholar
  30. 30.
    Mackway-Jones K. Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Alkalinisation in the management of tricyclic antidepressant overdose. J Accident Emerg Med. 1999;16:139–40. PubMed.Google Scholar
  31. 31.
    Adelsberg BR. Sedation and performance issues in the treatment of allergic conditions. Arch Intern Med. 1997;157:494–500.PubMedCrossRefGoogle Scholar
  32. 32.
    Weiler JM, Bloomfield JR, Woodworth GG, George G, Grant AR, Layton TA, et al. Effects of fexofenadine, diphenhydramine, and alcohol on driving performance: a randomized, placebo-controlled trial in the Iowa driving simulator. Ann Intern Med. 2000;132:354–63.PubMedCrossRefGoogle Scholar
  33. 33.
    Churchill JA, Gammon GD. The effect of antihistaminic drugs on convulsive seizures. JAMA. 1949;141:18–21.CrossRefGoogle Scholar
  34. 34.
    Wyngaarden JB, Seevers MH. The toxic effects of antihistaminic drugs. JAMA. 1951;145:277–82.CrossRefGoogle Scholar
  35. 35.
    Yasuhara A, Ochi A, Harada Y, Kobayashi Y. Infantile spasms associated with a histamine H1 antagonist. Neuropediatrics. 1998;29:320–1. PubMed.PubMedCrossRefGoogle Scholar
  36. 36.
    Olson KR, Kearney TE, Dyer JE, Benowitz NL, Blanc PD. Seizures associated with poisoning and drug overdose. Am J Emerg Med. 1993;11:565–8. PubMed.PubMedCrossRefGoogle Scholar
  37. 37.
    Goetz CM, Lopez G, Dean BS, Krenzelok EP. Accidental childhood death from diphenhydramine overdosage. Am J Emerg Med. 1990;8:321–2. PubMed.PubMedCrossRefGoogle Scholar
  38. 38.
    Krenzelok EP, Anderson GM, Mirick M. Massive diphenhydramine overdose resulting in death. Ann Emerg Med. 1982;11:212–3.PubMedCrossRefGoogle Scholar
  39. 39.
    Winn RE, McDonnell KP. Fatality secondary to massive overdose of dimenhydrinate. Ann Emerg Med. 1993;22:1481–4.PubMedCrossRefGoogle Scholar
  40. 40.
    Finkelstein Y, Hutson J, Freedman S, Wax P, Brent J. Drug-induced seizures in children and adolescents presenting for emergency care: current and emerging trends. Clin Toxicol. 2013;51:761–6.CrossRefGoogle Scholar
  41. 41.
    Miyawaki E, Tarsy D. Tardive dyskinesia and other drug-related movement disorders. In: Samuels MA, editor. Office practice of neurology. New York: Churchill Livingstone; 1996. p. 666–7.Google Scholar
  42. 42.
    Coyle JT, Snyder SH. Antiparkinsonian drugs: inhibition of dopamine uptake in the corpus striatum as a possible mechanism of action. Science. 1969;166:899–901. PubMed.PubMedCrossRefGoogle Scholar
  43. 43.
    Shishido S, Oishi R, Saeki K. In vivo effects of some histamine H1-receptor antagonists on monoamine metabolism in the mouse brain. Naunyn-Schmiedebergs Arch Pharmacol. 1991;343:185–9. PubMed.PubMedCrossRefGoogle Scholar
  44. 44.
    Symchowicz S, Korduba CA, Veals J. Inhibition of dopamine uptake into synaptosomes of rat corpus striatum by chlorpheniramine and its structural analogs. Life Sciences 1. 1971;10:35–42. PubMed.CrossRefGoogle Scholar
  45. 45.
    Barone DA, Raniolo J. Facial dyskinesia from overdose of an antihistamine [Letter]. N Engl J Med. 1980;303:107.PubMedGoogle Scholar
  46. 46.
    Brait KA, Zagerman AJ. Dyskinesias after antihistamine use. N Engl J Med. 1977;296:111.PubMedGoogle Scholar
  47. 47.
    Etzel JV. Diphenhydramine-induced acute dystonia. Pharmacotherapy. 1994;14:492–6. PubMed.PubMedGoogle Scholar
  48. 48.
    Favis GR. Facial dyskinesia related to antihistamine (Letter). N Engl J Med. 1976;294:730.PubMedGoogle Scholar
  49. 49.
    Granacher Jr RP. Facial dyskinesia after antihistamines [Letter]. N Engl J Med. 1977;296:516.PubMedGoogle Scholar
  50. 50.
    Joseph MM, King WD. Dystonic reaction following recommended use of a cold syrup. Ann Emerg Med. 1995;26:749–51. PubMed.PubMedCrossRefGoogle Scholar
  51. 51.
    Lavenstein BL, Cantor FK. Acute dystonia. An unusual reaction to diphenhydramine. JAMA. 1976;236:291. PubMed.PubMedCrossRefGoogle Scholar
  52. 52.
    Roila F, Donati D, Basurto C, Del Favero A. Diphenhydramine and acute dystonia [Letter]. Ann Intern Med. 1989;111:92–3.PubMedCrossRefGoogle Scholar
  53. 53.
    Sovner RD. Dyskinesia associated with chronic antihistamine use [Letter]. N Engl J Med. 1976;294:113.Google Scholar
  54. 54.
    Thach BT, Chase TN, Bosma JF. Oral facial dyskinesia associated with prolonged use of antihistaminic decongestants. N Engl J Med. 1975;293:486–7. PubMed.PubMedCrossRefGoogle Scholar
  55. 55.
    Zavitz M, Lindsay C, McGuigan M. Acute diphenhydramine ingestion in children. Vet Hum Toxicol. 1989;31:349.Google Scholar
  56. 56.
    Clark R, Vance M. Massive diphenhydramine poisoning resulting in a wide-complex tachycardia: successful treatment with sodium bicarbonate. Ann Emerg Med. 1992;21:318–21.PubMedCrossRefGoogle Scholar
  57. 57.
    Mullins ME, Pinnick RV, Terhes JM. Life-threatening diphenhydramine overdose treated with charcoal hemoperfusion and hemodialysis. Ann Emerg Med. 1999;33:104–7.PubMedCrossRefGoogle Scholar
  58. 58.
    Craft T. Torsade de pointes after astemizole overdose. BMJ. 1986;292:660.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Valen G, Kaszaki J, Szabo I, Nagy S, Vaage J. Histamine release and its effects in ischaemia-reperfusion injury of the isolated rat heart. Acta Physiol Scand. 1994;150:413–24.PubMedCrossRefGoogle Scholar
  60. 60.
    Davies AJ, Harindra V, McEwan A, Ghose RR. Cardiotoxic effect with convulsions in terfenadine overdose. BMJ. 1989;298:325.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Simons F, Keselman M, Giddins N, Pelech A, Simons K. Astemizole-induced torsade de pointes. Lancet. 1988;2:624.PubMedCrossRefGoogle Scholar
  62. 62.
    Snook J, Coothman-Burrell D, Watkins J, Colin-Jones D. Torsades de pointes ventricular tachycardia associated with astemizole overdose. Br J Clin Pract. 1988;42:257–9.PubMedGoogle Scholar
  63. 63.
    McCabe JL, Cobaugh DJ, Menegazzi JJ, Fata J. Experimental tricyclic antidepressant toxicity: a randomized, controlled comparison of hypertonic saline solution, sodium bicarbonate, and hyperventilation. Ann Emerg Med. 1998;32:329–33. PubMed.Google Scholar
  64. 64.
    Taglialatela M, Castaldo P, Pannaccione A, Giorgio G, Genovese A, Marone G, et al. Cardiac ion channels and antihistamines: possible mechanisms of cardiotoxicity. Clin Exp Allergy. 1999;29:182–9.PubMedCrossRefGoogle Scholar
  65. 65.
    Emadian SM, Caravati EM, Herr RD. Rhabdomyolysis: a rare adverse effect of diphenhydramine overdose. Am J Emerg Med. 1996;14:574–6.PubMedCrossRefGoogle Scholar
  66. 66.
    Khosla U, Ruel KS, Hunt DP. Antihistamine-induced rhabdomyolysis. South Med J. 2003;96:1023–6. PubMed.PubMedCrossRefGoogle Scholar
  67. 67.
    Kim HJ, Oh SH, Youn CS, Wee JH, Kim JH, Jeong WJ, et al. The associative factors of delayed-onset rhabdomyolysis in patients with doxylamine overdose. Am J Emerg Med. 2011;29:903–7. PubMed.PubMedCrossRefGoogle Scholar
  68. 68.
    Leybishkis B, Fasseas P, Ryan KF. Doxylamine overdose as a potential cause of rhabdomyolysis. Am J Med Sci. 2001;322:48–9. PubMed.PubMedCrossRefGoogle Scholar
  69. 69.
    Pragst F, Herre S, Bakdash A. Poisonings with diphenhydramine–a survey of 68 clinical and 55 death cases. Forensic Sci Int. 2006;161:189–97. PubMed.PubMedCrossRefGoogle Scholar
  70. 70.
    Stucka KR, Mycyk MB, Leikin JB, Pallasch EM. Rhabdomyolysis associated with unintentional antihistamine overdose in a child. Pediatr Emerg Care. 2003;19:25–6. PubMed.PubMedCrossRefGoogle Scholar
  71. 71.
    Frankel D, Dolgin J, Murray BM. Non-traumatic rhabdomyolysis complicating antihistamine overdose. J Toxicol Clin Toxicol. 1993;31:493–6.PubMedCrossRefGoogle Scholar
  72. 72.
    Mendoza FS, Atiba JO, Krensky AM, Scannell LM. Rhabdomyolysis complicating doxylamine overdose. Clin Pediatr. 1987;26:595–7. PubMed.CrossRefGoogle Scholar
  73. 73.
    Soto LF, Miller CH, Ognibere AJ. Severe rhabdomyolysis after doxylamine overdose. Postgrad Med. 1993;93:227–9. 32. PubMed.PubMedCrossRefGoogle Scholar
  74. 74.
    Arbiser JL, Goldstein AM, Gordon D. Thrombocytopenia following administration of phenytoin, dexamethasone and cimetidine: a case report and a potential mechanism. J Intern Med. 1993;234:91–4. PubMed.PubMedCrossRefGoogle Scholar
  75. 75.
    Gafter U, Komlos L, Weinstein T, Zevin D, Levi J. Thrombocytopenia, eosinophilia, and ranitidine. Ann Int Med. 1987;106:477. PubMed.Google Scholar
  76. 76.
    Gentilini G, Curtis BR, Aster RH. An antibody from a patient with ranitidine-induced thrombocytopenia recognizes a site on glycoprotein IX that is a favored target for drug-induced antibodies. Blood. 1998;92:2359–65. PubMed.PubMedGoogle Scholar
  77. 77.
    Gibson PR, Pidcock ME. Immune-mediated thrombocytopenia associated with ranitidine therapy. Med J Aust. 1986;145:661–2. PubMed.PubMedGoogle Scholar
  78. 78.
    Glotzbach RE. Cimetidine-induced thrombocytopenia. South Med J. 1982;75:232–4. PubMed.PubMedCrossRefGoogle Scholar
  79. 79.
    Isaacs AJ. Cimetidine and thrombocytopenia. Br Med J. 1980;280:294. PubMed Pubmed Central PMCID: PMC1600144.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Mann HJ, Schneider JR, Miller JB, Delaney JP. Cimetidine-associated thrombocytopenia. Drug Intell Clin Pharm. 1983;17:126–8. PubMed.PubMedGoogle Scholar
  81. 81.
    Wong YY, Lichtor T, Brown FD. Severe thrombocytopenia associated with phenytoin and cimetidine therapy. Surg Neurol. 1985;23:169–72. PubMed.PubMedCrossRefGoogle Scholar
  82. 82.
    Reddy J, Bailey RR. Cimetidine and thrombocytopenia. N Z Med J. 1980;91:232. PubMed.PubMedGoogle Scholar
  83. 83.
    Shalev O, Seror D. Cimetidine and ranitidine may not cross-react to cause thrombocytopenia. J Intern Med. 1991;230:87–8. PubMed.PubMedCrossRefGoogle Scholar
  84. 84.
    Spychal RT, Wickham NW. Thrombocytopenia associated with ranitidine. Br Med J (Clin Res Ed). 1985;291:1687. PubMed Pubmed Central PMCID: PMC1418797.CrossRefGoogle Scholar
  85. 85.
    Yates VM, Kerr RE. Cimetidine and thrombocytopenia. Br Med J. 1980;280:1453. PubMed Pubmed Central PMCID: PMC1601787.PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Yue CP, Mann KS, Chan KH. Severe thrombocytopenia due to combined cimetidine and phenytoin therapy. Neurosurgery. 1987;20:963–5. PubMed.PubMedCrossRefGoogle Scholar
  87. 87.
    Chandrasekhara KL, Iyer SK, Macchia RJ. Leucopenia and thrombocytopenia with cimetidine. J Natl Med Assoc. 1981;73:92. 8. PubMed Pubmed Central PMCID: PMC2552636.PubMedPubMedCentralGoogle Scholar
  88. 88.
    Chang HK, Morrison SL. Bone-marrow suppression associated with cimetidine. Ann Intern Med. 1979;91:580. PubMed.PubMedCrossRefGoogle Scholar
  89. 89.
    Collen MJ. Cimetidine-associated thrombocytopenia and leukopenia. West J Med. 1980;132:257–8. PubMed Pubmed Central PMCID: PMC1272052.PubMedPubMedCentralGoogle Scholar
  90. 90.
    James C, Prout BJ. Marrow suppression and intravenous cimetidine. Lancet. 1978;1:987. PubMed.PubMedCrossRefGoogle Scholar
  91. 91.
    Mar DD, Brandstetter RD, Miskovitz PF, Fotino M. Cimetidine-induced, immune-mediated leukopenia and thrombocytopenia. South Med J. 1982;75:1283–5. PubMed.PubMedCrossRefGoogle Scholar
  92. 92.
    Oymak O, Akpolat T, Arik N, Yasavul U, Turgan C, Caglar S. Reversible neutropenia and thrombocytopenia during famotidine treatment. Ann Pharmacother. 1994;28:406–7. PubMed.PubMedCrossRefGoogle Scholar
  93. 93.
    Pixley JS, MacKintosh FR, Sahr EA, Zanjani ED. Mechanism of ranitidine associated anemia. Am J Med Sci. 1989;297:369–71. PubMed.PubMedCrossRefGoogle Scholar
  94. 94.
    Rate R, Bonnell M, Chervenak C, Pavinich G. Cimetidine and hematologic effects. Ann Intern Med. 1979;91:795. PubMed.PubMedCrossRefGoogle Scholar
  95. 95.
    George JN, Raskob GE, Shah SR, Rizvi MA, Hamilton SA, Osborne S, et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med. 1998;129:886–90. PubMed.PubMedCrossRefGoogle Scholar
  96. 96.
    Gafter U, Zevin D, Komlos L, Livni E, Levi J. Thrombocytopenia associated with hypersensitivity to ranitidine: possible cross-reactivity with cimetidine. Am J Gastroenterol. 1989;84:560–2. PubMed.PubMedGoogle Scholar
  97. 97.
    Burnakis TG. Inaccurate assessment of drug-induced thrombocytopenia: reason for concern. Ann Pharmacother. 1994;28:726–9. PubMed.PubMedCrossRefGoogle Scholar
  98. 98.
    Iyer SK, Chandrasekhara KL. Leukopenia with cimetidine. J Natl Med Assoc. 1980;72:805–6. PubMed Pubmed Central PMCID: PMC2552491.PubMedPubMedCentralGoogle Scholar
  99. 99.
    Johnson NM, Black AE, Hughes ASB, Clarke SW. Leucopenia with cimetidine. Lancet. 1977;310:1226–7.CrossRefGoogle Scholar
  100. 100.
    Khokhar N, Akavaram NR. Cimetidine-induced leukopenia: case reports. Mil Med. 1980;145:853–5. PubMed.PubMedGoogle Scholar
  101. 101.
    Lopez-Luque A, Rodriguez-Cuartero A, Perez-Galvez N, Pomores Mora J, Pena-Yanez A. Cimetidine and bone-marrow toxicity. Lancet. 1978;1:444. PubMed.PubMedCrossRefGoogle Scholar
  102. 102.
    Byron JW. Pharmacodynamic basis for the interaction of cimetidine with the bone marrow stem cells (CFUS). Exp Hematol. 1980;8:256–63. PubMed.PubMedGoogle Scholar
  103. 103.
    Syed H, Som S, Khan N, Faltas W. Doxylamine toxicity: seizure, rhabdomyolysis and false positive urine drug screen for methadone. BMJ Case Rep. 2009;2009:bcr0920080879.Google Scholar
  104. 104.
    Brahm NC, Yeager LL, Fox MD, Farmer KC, Palmer TA. Commonly prescribed medications and potential false-positive urine drug screens. Am J Health Syst Pharm. 2010;67:1344.PubMedCrossRefGoogle Scholar
  105. 105.
    Herring C, Muzyk AJ, Johnston C. Interferences with urine drug screens. J Pharm Pract. 2011;24:102–8.PubMedCrossRefGoogle Scholar
  106. 106.
    Kelner M. Positive diphenhydramine interference in the EMIT-dau assay. Clin Chem. 1984;30:1430.PubMedGoogle Scholar
  107. 107.
    Sorisky A, Watson D. Positive diphenhydramine interference in the EMIT-st assay for tricyclic antidepressants in serum. Clin Chem. 1986;32:715.PubMedGoogle Scholar
  108. 108.
    McKeown NJ, West PL, Hendrickson RG, Horowitz BZ. Survival after diphenhydramine ingestion with hemodialysis in a toddler. J Med Toxicol. 2011;7:147–50.PubMedCrossRefGoogle Scholar
  109. 109.
    Cowen PJ. Toxic psychosis with antihistamines reversed by physostigmine. Postgrad Med J. 1979;55:556–7. PubMed Pubmed Central PMCID: PMC2428090.PubMedPubMedCentralCrossRefGoogle Scholar
  110. 110.
    Burns MJ, Linden CH, Graudins A, Brown RM, Fletcher KE. A comparison of physostigmine and benzodiazepines for the treatment of anticholinergic poisoning. Ann Emerg Med. 2000;35:374–81. PubMed.PubMedCrossRefGoogle Scholar
  111. 111.
    Newton RW. Physostigmine salicylate in the treatment of tricyclic antidepressant overdosage. JAMA. 1975;231:941–3. PubMed.PubMedCrossRefGoogle Scholar
  112. 112.
    Pentel P, Peterson CD. Asystole complicating physostigmine treatment of tricyclic antidepressant overdose. Ann Emerg Med. 1980;9:588–90. PubMed.PubMedCrossRefGoogle Scholar
  113. 113.
    Walker WE, Levy RC, Hanenson IB. Physostigmine–its use and abuse. JACEP. 1976;5:436–9. PubMed.PubMedCrossRefGoogle Scholar
  114. 114.
    Walker A, Delle Donne A, Douglas E, Spicer K, Pluim T. Novel use of dexmedetomidine for the treatment of anticholinergic toxidrome. J Med Toxicol. 2014;10:406–10.PubMedPubMedCentralCrossRefGoogle Scholar
  115. 115.
    Blake KV, Massey KL, Hendeles L, Nickerson D, Neims A. Relative efficacy of phenytoin and phenobarbital for the prevention of theophylline-induced seizures in mice. Ann Emerg Med. 1988;17:1024–8. PubMed.PubMedCrossRefGoogle Scholar
  116. 116.
    Citak A, Soysal DD, Ucsel R, Karabocuoglu M, Uzel N. Efficacy of long duration resuscitation and magnesium sulphate treatment in amitriptyline poisoning. Eur J Emerg Med. 2002;9:63–6. PubMed.PubMedCrossRefGoogle Scholar
  117. 117.
    Sarisoy O, Babaoglu K, Tugay S, Barn E, Gokalp AS. Efficacy of magnesium sulfate for treatment of ventricular tachycardia in amitriptyline intoxication. Pediatr Emerg Care. 2007;23:646–8. PubMed.PubMedCrossRefGoogle Scholar
  118. 118.
    Poluzzi E, Raschi E, Moretti U, De Ponti F. Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf. 2009;18:512–8. PubMed.PubMedCrossRefGoogle Scholar
  119. 119.
    Abdelmalek DMD, Schwarz ESMD, Sampson CMD, Halcomb SEMD, McCammon CP, Arroyo-Plasencia AMD, et al. Life-threatening diphenhydramine toxicity presenting with seizures and a wide complex tachycardia improved with intravenous fat emulsion. Am J Ther. 2014;21:542–4.PubMedCrossRefGoogle Scholar
  120. 120.
    Abdi A, Rose E, Levine M. Diphenhydramine overdose with intraventricular conduction delay treated with hypertonic sodium bicarbonate and IV lipid emulsion. West J Emerg Med. 2014;15:855.PubMedPubMedCentralCrossRefGoogle Scholar
  121. 121.
    Jolliff H, De Lucia A, Thomas T, editors. Lipid emulsion in the treatment of diphenhydramine toxicity. In: Clinical toxicology. New York: Informa Healthcare 52 Vanderbilt Ave; 2010.Google Scholar
  122. 122.
    Levine M, Skolnik AB, Ruha A-M, Bosak A, Menke N, Pizon AF. Complications following antidotal use of intravenous lipid emulsion therapy. J Med Toxicol. 2014;10:10–4.PubMedCrossRefGoogle Scholar
  123. 123.
    Chiladakis JA, Spiroulias G, Koutsogiannis N, Zagli F, Alexopoulos D. Short-coupled variant of Torsade de Pointes as a cause of electrical storm and aborted sudden cardiac death: insights into mechanism and treatment. Hellenic J Cardiol. 2008;49:360–4. PubMed.PubMedGoogle Scholar
  124. 124.
    Omar HR, Sprenker C, Karlnoski R, Mangar D, Camporesi EM. The use of isoproterenol and phenytoin to reverse torsade de pointes. Am J Emerg Med. 2014;32:683e5–7. PubMed.CrossRefGoogle Scholar
  125. 125.
    Cosio FG, Goicolea A, Lopez Gil M, Kallmeyer C, Barroso JL. Suppression of Torsades de Pointes with verapamil in patients with atrio-ventricular block. Eur Heart J. 1991;12:635–8. PubMed.PubMedCrossRefGoogle Scholar
  126. 126.
    Liao WB, Bullard MJ, Kuo CT, Hsiao CT, Chu PH, Chiang CW. Anticholinergic overdose induced torsade de pointes successfully treated with verapamil. Jpn Heart J. 1996;37:925–31. PubMed.PubMedCrossRefGoogle Scholar
  127. 127.
    Brosch SF, Studenik C, Heistracher P. Abolition of drug-induced early afterdepolarizations by potassium channel activators in guinea-pig Purkinje fibres. Clin Exp Pharmacol Physiol. 1998;25:225–30. PubMed.PubMedCrossRefGoogle Scholar
  128. 128.
    Carlsson L, Abrahamsson C, Drews L, Duker G. Antiarrhythmic effects of potassium channel openers in rhythm abnormalities related to delayed repolarization. Circulation. 1992;85:1491–500. PubMed.PubMedCrossRefGoogle Scholar
  129. 129.
    Panzeri C, Bacis G, Ferri F, Rinaldi G, Persico A, Uberti F, et al. Extracorporeal life support in a severe Taxus baccata poisoning. Clin Toxicol. 2010;48:463–5. PubMed.CrossRefGoogle Scholar
  130. 130.
    Tsai FC, Wang YC, Huang YK, Tseng CN, Wu MY, Chang YS, et al. Extracorporeal life support to terminate refractory ventricular tachycardia. Crit Care Med. 2007;35:1673–6. PubMed.PubMedCrossRefGoogle Scholar
  131. 131.
    Ebert SN, Liu XK, Woosley RL. Female gender as a risk factor for drug-induced cardiac arrhythmias: evaluation of clinical and experimental evidence. J Womens Health. 1998;7:547–57.PubMedCrossRefGoogle Scholar
  132. 132.
    Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA. 1993;270:2590–7. PubMed.PubMedCrossRefGoogle Scholar
  133. 133.
    Agostini JV, Leo-Summers LS, Inouye SK. Cognitive and other adverse effects of diphenhydramine use in hospitalized older patients. Arch Intern Med. 2001;161:2091–7. PubMed.PubMedCrossRefGoogle Scholar
  134. 134.
    Slugg PH, Haug MT, Pippenger CE. Ranitidine pharmacokinetics and adverse central nervous system reactions. Arch Int Med. 1992;152:2325–9.CrossRefGoogle Scholar
  135. 135.
    Seto A, Einarson T, Koren G. Pregnancy outcome following first trimester exposure to antihistamines: meta-analysis. Am J Perinatol. 1997;14:119–24.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Department of Emergency Medicine / Division of Medical ToxicologyIndiana University School of MedicineIndianapolisUSA

Personalised recommendations